In recent years, several immunotherapies have been approved for the treatment of lung cancer, namely PD-1 checkpoint inhibitors nivolumab and pembrolizumab and the anti-CTLA-4 inhibitor ipilimumab. Here, PDCD1 is linked to lung carcinoma.